AI-generated analysis. Always verify with the original filing.
MBX Biosciences, Inc. furnished its results of operations under Item 2.02 via Exhibit 99.1 press release dated March 12, 2026. This disclosure provides key financial metrics relevant to investor assessment of the company's performance.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Current Report on Form 8-K (including Exhibit 99.1 attached hereto), is intended to be furnished and shall not be deemed "filed" for purposes of Section
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release Issued by MBX Biosciences, Inc. on March 12, 2026 104 Cover Page Int